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Non-enzymatic glycation is one of the post-translational modifications (PTMs) less 
frequently studied. An innovative approach for quantitative analysis of glycated proteins 
(GP) in clinical samples (serum, plasma and red blood cells) is here presented. It is based 
on relative quantitation of samples between two glycation states by differential labeling 
with light and heavy glucose (12C6- and 
13C6-glucose). Then, both sets of samples are 
pooled to carry out analysis by a shotgun proteomics workflow. This consists of in-
solution digestion with endoproteinase Glu-C, selective enrichment of glycated peptides 
by boronate affinity chromatography (BAC), and analysis by RP-LC-ESI-MS/MS with 
an Orbitrap® mass analyzer (MS2 HCD higher energy collisional dissociation and data-
dependent MS3 operation modes). A similar labeling efficiency has been observed with 
both isotopic glucose forms under the same operating conditions, which is essential for 
the applicability of the method. The identification and quantitation of GP is possible 
as the resulting peptides provide doublet signals in MS (labeling with light and heavy 
glucose) with a mass shift of +6, +3 or +2 Da depending on the peptide charge. With 
this methodology, it was possible to identify different GP such as serum albumin (with 
the five preferred glycation sites), immunoglobulins, haptoglobin, serotransferrin, 
complement C-3 and C-8 precursors, α-2-HS-glycoprotein or apolipoprotein A-1. These 
proteins are representative targets to compare between samples with different glycation 
states. This approach has also been applied to the analysis of clinical samples after 
depletion of more concentrated proteins. Further research is focused on the capability 
of the method to monitor the concentration of GP as well as to predict new potential 
targets for glycation. This can be especially interesting because it could be applied 
with prognosis/diagnosis purposes linked to pathological disorders related to glycemic 
control.
